Stonegate Investment Group LLC Sells 2,544 Shares of Sanofi (NASDAQ:SNY)

Stonegate Investment Group LLC trimmed its holdings in shares of Sanofi (NASDAQ:SNY) by 28.9% in the first quarter, according to its most recent filing with the SEC. The firm owned 6,264 shares of the company’s stock after selling 2,544 shares during the period. Stonegate Investment Group LLC’s holdings in Sanofi were worth $347,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Invesco Ltd. lifted its holdings in shares of Sanofi by 3.5% during the 4th quarter. Invesco Ltd. now owns 12,059,283 shares of the company’s stock worth $581,619,000 after acquiring an additional 408,752 shares during the period. Bank of America Corp DE lifted its holdings in shares of Sanofi by 3.8% during the 4th quarter. Bank of America Corp DE now owns 12,017,140 shares of the company’s stock worth $579,587,000 after acquiring an additional 441,637 shares during the period. Price T Rowe Associates Inc. MD lifted its holdings in shares of Sanofi by 88.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 10,843,682 shares of the company’s stock worth $522,991,000 after acquiring an additional 5,091,304 shares during the period. Boston Partners lifted its holdings in shares of Sanofi by 86.4% during the 4th quarter. Boston Partners now owns 5,396,531 shares of the company’s stock worth $260,607,000 after acquiring an additional 2,501,073 shares during the period. Finally, Franklin Resources Inc. lifted its holdings in shares of Sanofi by 10.8% during the 4th quarter. Franklin Resources Inc. now owns 3,776,982 shares of the company’s stock worth $182,164,000 after acquiring an additional 369,530 shares during the period. 14.04% of the stock is owned by institutional investors.

Sanofi Trading Up 0.5%

Shares of Sanofi stock opened at $47.86 on Friday. The company has a quick ratio of 0.69, a current ratio of 1.37 and a debt-to-equity ratio of 0.16. The stock has a market capitalization of $117.37 billion, a P/E ratio of 17.09, a price-to-earnings-growth ratio of 0.98 and a beta of 0.50. Sanofi has a 12-month low of $45.80 and a 12-month high of $60.12. The company has a 50-day simple moving average of $51.23 and a 200 day simple moving average of $52.03.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.04. The firm had revenue of $10.41 billion during the quarter, compared to analysts’ expectations of $9.79 billion. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The company’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.78 EPS. Research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Shareholders of record on Friday, May 9th were given a $2.0369 dividend. This represents a yield of 3.1%. The ex-dividend date was Friday, May 9th. This is a boost from Sanofi’s previous annual dividend of $1.48. Sanofi’s dividend payout ratio (DPR) is presently 57.14%.

Analyst Ratings Changes

SNY has been the subject of a number of analyst reports. Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a report on Tuesday, June 3rd. The Goldman Sachs Group assumed coverage on shares of Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 target price for the company. Morgan Stanley set a $56.00 target price on shares of Sanofi in a research report on Monday, June 2nd. BNP Paribas assumed coverage on shares of Sanofi in a research report on Tuesday, April 15th. They set an “outperform” rating and a $65.00 target price for the company. Finally, Hsbc Global Res upgraded shares of Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Three investment analysts have rated the stock with a hold rating, three have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $61.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.